Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366388 | 0.98 | KDM4E (0.54) | KDM4EALDH1A1GAATAAR1IDO1 | |
| SCHEMBL3366927 | 0.93 | TAAR1 (0.53) | KDM4EALDH1A1GAATAAR1IDO1 | |
| SCHEMBL27945752 | 0.85 | ACP3 (0.46) | KDM4EALDH1A1GAATAAR1IDO1 | |
| SCHEMBL4097081 | 0.85 | GBA1 (0.57) | TAAR1HTR2CHTR2BMAOB | |
| SCHEMBL27297055 | 0.85 | HTT (0.49) | KDM4EALDH1A1GAATAAR1IDO1 | |
| SCHEMBL14028146 | 0.85 | HTT (0.49) | KDM4EALDH1A1GAATAAR1IDO1 | |
| SCHEMBL16024727 | 0.85 | TAAR1 (0.46) | KDM4EALDH1A1GAATAAR1IDO1 | |
| Hydrochloric Acid SCHEMBL18280118 | 0.84 | HTR2C (0.57) | IDO1HTR2CHTR2BMAOB | |
| SCHEMBL21430763 | 0.83 | MAOB (0.61) | KDM4EALDH1A1GAATAAR1IDO1 | |
| SCHEMBL11986976 | 0.83 | ALDH1A1 (0.51) | KDM4EALDH1A1GAAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | GRUENENTHAL GMBH (DE) | 2010-04-29 | — | — | US | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | KCNQ1, KCNQ3, KCNQ2 | KDM4E 641/4885ALDH1A1 2284/4885GAA 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.